Y-MABS THERAPEUTICS I

Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

30 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023

21 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab

02 Feb 2023 08:00:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA

04 Jan 2023 15:01:00 By Nasdaq GlobeNewswire

Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 08:00:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe

21 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS/LM Metastasis from Neuroblastoma in Europe

16 Dec 2022 15:01:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Pipeline Update

14 Dec 2022 08:00:01 By Nasdaq GlobeNewswire

Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China

08 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

Y-mAbs to Host Annual Research and Development Day in New York

06 Dec 2022 08:00:01 By Nasdaq GlobeNewswire

Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application

01 Dec 2022 16:34:16 By Nasdaq GlobeNewswire

Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

07 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022

02 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab

28 Oct 2022 14:33:33 By Nasdaq GlobeNewswire

Y-mAbs Announces Pivotal Data for Omburtamab

03 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil

26 Sep 2022 08:00:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab

01 Sep 2022 15:05:00 By Nasdaq GlobeNewswire

Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma

30 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

08 Aug 2022 15:05:02 By Nasdaq GlobeNewswire

Y-mAbs to Announce Second Quarter 2022 Financial and Operating Results on August 8, 2022

02 Aug 2022 08:00:00 By Nasdaq GlobeNewswire